Japanese pharmaceutical company Takeda is evaluating India as a potential location for global clinical trials, aiming to accelerate drug approvals in the world’s most populous nation. The move aligns with India’s growing clinical trial market, which is projected to exceed $2 billion by 2030 due to its diverse patient pools, cost efficiency, and expanding hospital infrastructure
.
Takeda’s India head, Annapurna Das, confirmed the company is exploring opportunities to integrate India’s clinical trial ecosystem into its global R&D pipeline. The initiative could enhance patient access to innovative therapies in oncology, neuroscience, gastrointestinal health, and inflammation. Das emphasized India’s strategic importance but did not disclose financial details of planned investments.

The company plans to launch key cancer drugs in India over the next two to three years, including a lung cancer treatment scheduled for release this year. A dengue vaccine developed in partnership with local manufacturer Biological E. also awaits regulatory approval.

Takeda recently established an innovation center in Bengaluru, employing over 500 staff in AI, data science, and engineering roles, with plans to expand to 750 employees. The facility supports Takeda’s global digital transformation while leveraging India’s tech talent.

The strategy reflects broader industry trends toward decentralizing clinical trials and engaging emerging markets earlier in drug development. If implemented, Takeda’s approach could reduce time-to-market for new therapies while strengthening India’s role in global pharmaceutical innovation.

Source: Reuters.